{
    "clinical_study": {
        "@rank": "26679", 
        "arm_group": [
            {
                "arm_group_label": "BAY1002670 [0.1mg]", 
                "arm_group_type": "Experimental", 
                "description": "0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days"
            }, 
            {
                "arm_group_label": "BAY1002670 [0.5mg]", 
                "arm_group_type": "Experimental", 
                "description": "0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days"
            }, 
            {
                "arm_group_label": "BAY1002670 [1.0mg]", 
                "arm_group_type": "Experimental", 
                "description": "1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days"
            }, 
            {
                "arm_group_label": "BAY1002670 [2.0mg]", 
                "arm_group_type": "Experimental", 
                "description": "2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days"
            }, 
            {
                "arm_group_label": "BAY1002670 [5.0mg]", 
                "arm_group_type": "Experimental", 
                "description": "5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "Effects of BAY1002670 on bleeding pattern: non-bleeding rate; on endometrium; on ovarian\n      function; return of menstrual bleeding after treatment; safety and tolerability; PK/PD\n      (pharmacokinetic/pharmacodynamic) relationship"
        }, 
        "brief_title": "Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Leiomyoma", 
        "condition_browse": {
            "mesh_term": [
                "Leiomyoma", 
                "Myofibroma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy female subjects\n\n          -  Sterilized by tubal ligation\n\n          -  Age 18-45 years\n\n          -  Body mass index (BMI) at screening: \u2265 18 and \u2264 32 kg/m\u00b2\n\n          -  At least 3 consecutive regular menstrual cycles with a cycle length of 24 - 35 days\n             before first screening examination according to the subject's history\n\n          -  Absence of clinically relevant abnormal findings in the pre-treatment endometrial\n             biopsy\n\n        Exclusion Criteria:\n\n          -  Regular use of medicines (incl. anabolics)\n\n          -  Incompletely cured pre-existing diseases for which it can be assumed that the\n             absorption, distribution, metabolism, elimination and effects of the study drugs will\n             not be normal\n\n          -  Amenorrhea for more than 3 months within the last 6 months before the first screening\n             examination\n\n          -  Lacking suitability for frequent transvaginal ultrasonography (TVU) examinations\n\n          -  Clinically relevant findings (e.g. blood pressure, electrocardiogram [ECG], physical\n             and gynecological examination, laboratory examination)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "73", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01816815", 
            "org_study_id": "14723", 
            "secondary_id": "2011-001760-22"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BAY1002670 [0.1mg]", 
                    "BAY1002670 [0.5mg]", 
                    "BAY1002670 [1.0mg]", 
                    "BAY1002670 [2.0mg]", 
                    "BAY1002670 [5.0mg]"
                ], 
                "intervention_name": "BAY1002670", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "PK/PD", 
            "BAY1002670"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }, 
            {
                "description": "Click here to find results for studies related to Bayer Healthcare products.", 
                "url": "http://healthcare.bayer.com/scripts/pages/en/research_development/clinical_trials/trial_finder/index.php"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "zip": "2060"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neu-Ulm", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "89231"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neuss", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "41450"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belfast", 
                        "country": "United Kingdom", 
                        "zip": "BT2 7BA"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "6", 
        "official_title": "A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Non-bleeding rate (i.e. women without bleeding from treatment day 9 until the end of treatment)", 
            "safety_issue": "No", 
            "time_frame": "After three months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01816815"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Return of menstrual bleeding after treatment", 
            "safety_issue": "No", 
            "time_frame": "Up to two months after last treatment"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}